Evidence map›Paper›PMID 15122319›Full record

ArticleOncogene2004

Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin.

Shannon Reagan-Shaw, Farrukh Afaq, Moammir Hasan Aziz, Nihal Ahmad

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Role of Phytochemicals in Cancer Chemoprevention: Insights.Antioxidants (Basel, Switzerland) · 2021
    Review
  10. Review
  11. Review
  12. Inhibitory effect of simvastatin in nasopharyngeal carcinoma cells.Experimental and therapeutic medicine · 2019
    Article
  13. Resveratrol as a Multifunctional Topical Hypopigmenting Agent.International journal of molecular sciences · 2019
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Phytochemicals in Skin Cancer Prevention and Treatment: An Updated Review.International journal of molecular sciences · 2018
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shannon Reagan-ShawDepartment of Dermatology, University of Wisconsin, Madison, WI 53706, USA.
Farrukh Afaq
Moammir Hasan Aziz
Nihal Ahmad
University of Wisconsin–Madison · US

Funding

Chemoprevention of Photocarcinogenesis by ResveratrolR03CA098368 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI AHMAD, NIHAL · 2002 to 2003
$146k
Skin Cancer Chemoprevention by SanguinarineR03CA099076 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI AHMAD, NIHAL · 2003 to 2004
$146k
NCI NIH HHS R03 CA 98368NCI NIH HHS R03 CA 99076
6 · The paper itself

Abstract

Multiple exposures to solar ultraviolet (UV) radiation cause critical damages that may lead to the development of several cutaneous disorders including skin cancer, the most frequently diagnosed malignancy in the USA. Therefore, efforts are needed to: (i) study the mechanism(s) of UV-mediated cutaneous damages, and (ii) design novel approaches for the management of skin cancer. 'Chemoprevention' via plant-based agents may be a useful approach for the management of neoplasia. Here, we evaluated the involvement of cell cycle regulatory molecules during resveratrol-mediated protection from multiple exposures of UVB (180 mJ/cm(2); on alternate days x 7 exposures) radiations in the SKH-1 hairless mouse skin. Resveratrol was topically applied on the skin of SKH-1 hairless mice at a dose of 10 micromol/mouse (in 0.2 ml acetone; 30 min prior to each UVB exposure). Studies were performed at 24 h following the last UVB exposure. Topical application of resveratrol resulted in significant decrease in UVB-induced bi-fold skin thickness, hyperplasia, and infiltration of leukocytes. The data from immunoblot and/or immunohistochemical analyses revealed that multiple exposure to UVB radiations causes significant upregulation in: (i) proliferating cell nuclear antigen (PCNA), a marker of cellular proliferation, and (ii) cyclin-dependent kinase (cdk)-2, -4 and -6, cyclin-D1, and cyclin-D2. Resveratrol treatment resulted in significant downregulation in UV-mediated increases in these critical cell cycle regulatory proteins. An interesting observation of this study was that resveratrol treatment resulted in a further stimulation of UVB-mediated increases in cyclin kinase inhibitor WAF1/p21 and tumor suppressor p53. Further, resveratrol was also found to cause significant decreases in UVB-mediated upregulation of: (i) the mitogen-activated protein kinase kinase, and (ii) the 42 kDa isotype of mitogen-activated protein kinase (MAPK). Thus, our data suggested that the antiproliferative effects of resveratrol might be mediated via modulation in the expression and function of cell cycle regulatory proteins cyclin-D1 and -D2, cdk-2, -4 and -6, and WAF1/p21. Our data further suggest that the modulation of cki-cyclin-cdk network by resveratrol may be associated with inhibition of the MAPK pathway. We suggest that resveratrol may be useful for the prevention of UVB-mediated cutaneous damages including skin cancer.

Indexed as

Administration, TopicalAnimalsBlotting, WesternCell CycleCyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent KinasesCyclinsDown-RegulationFemaleImmunohistochemistryLeukocytesMiceMice, HairlessMitogen-Activated Protein Kinase KinasesMolecular StructureProliferating Cell Nuclear AntigenCdkn1a protein, mouseCyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent KinasesCyclinsMitogen-Activated Protein Kinase KinasesProliferating Cell Nuclear AntigenResveratrolStilbenesTumor Suppressor Protein p53

Identifiers

PMID15122319
OpenAlexW2038019327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.